TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.

• TrumpRx is a new public-private drug pricing program launched by the Trump administration with Pfizer offering direct-to-consumer sales at reduced prices.
• Experts say it closely resembles existing DTC models like Mark Cuban's Cost Plus Drugs rather than being a novel approach.
• Since most patients rely on insurance rather than paying cash for prescriptions, the program likely won't have a major impact on the majority of drug purchasers.